Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180‐week follow‐up results from the phase 3, multicenter IMMspire study

Risankizumab, a humanized immunoglobin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit, is approved in Japan to treat numerous indications, including generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). Both GPP and EP are severe forms...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanaka, Keiichi, Okubo, Yukari, Yasuda, Ikuko, Saito, Nobuo, Messina, Izabella, Morita, Akimichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107196/
https://www.ncbi.nlm.nih.gov/pubmed/36514850
http://dx.doi.org/10.1111/1346-8138.16667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107196/
https://www.ncbi.nlm.nih.gov/pubmed/36514850
http://dx.doi.org/10.1111/1346-8138.16667

Ejemplares similares